Literature DB >> 33421691

Looking beyond pulmonary disease in COVID-19: A lesson from patients with cystic fibrosis.

Sara Manti1, Giuseppe Fabio Parisi2, Maria Papale2, Enza Mulè2, Donatella Aloisio2, Novella Rotolo2, Salvatore Leonardi2.   

Abstract

Coronavirus disease 2019 (COVID-19) caused more than 52.775.271 million confirmed cases, 1.293.106 deaths, globally, and afflicted 208 countries, areas, or territories; and almost three months have passed since the World Health Organisation (WHO) declared COVID-19 as a pandemic. Despite the dramatic and global impact of the Coronavirus, the knowledge about the SARS-CoV-2 infection has been improved remarkably. Herein, we provided the rationale for SARS-CoV-2 infection as endothelial dysfunction rather than respiratory disease. Accordingly, we strongly invited the researchers to look beyond pulmonary injury and shift their attention from respiratory disease to endothelial disorder. This strategy could be particularly relevant to identifying therapeutic weapons stabilizing the endothelium rather than the lungs.
Copyright © 2021 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  COVID-19; Cystic fibrosis; Endothelial dysfunction; Pulmonary disease; SARS-CoV-2 infection

Year:  2021        PMID: 33421691     DOI: 10.1016/j.mehy.2020.110481

Source DB:  PubMed          Journal:  Med Hypotheses        ISSN: 0306-9877            Impact factor:   1.538


  2 in total

1.  Discovering Common Pathophysiological Processes between COVID-19 and Cystic Fibrosis by Differential Gene Expression Pattern Analysis.

Authors:  Md Tanvir Hasan; Lway Faisal Abdulrazak; Mohammad Khursheed Alam; Md Rezwan Islam; Yeasmin Hena Sathi; Fahad Ahmed Al-Zahrani; Kawsar Ahmed; Francis M Bui; Mohammad Ali Moni
Journal:  Biomed Res Int       Date:  2022-04-29       Impact factor: 3.246

2.  Outcomes of SARS-CoV-2 infection in patients with cystic fibrosis: A multicenter retrospective research network study.

Authors:  Yousaf B Hadi; Dhairya A Lakhani; Syeda F Naqvi; Nida Ul Fatima; Arif R Sarwari
Journal:  Respir Med       Date:  2021-09-08       Impact factor: 3.415

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.